Latest news with #Neo
Business Wire
12 hours ago
- Business
- Business Wire
NeoGenomics Reports Second Quarter 2025 Results
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO) (the ' Company '), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2025. 'In the second quarter clinical revenue increased by 16% driven by sequential improvement in AUP, a record quarter for volumes, and NGS growth of 23%,' said Tony Zook, CEO of NeoGenomics. 'Strength in our Clinical business was largely offset by continuing pressure in pharma revenue that was beyond our initial assumptions, and a delay in our commercial launch of PanTracer™ Liquid Biopsy that impacted our expected NGS revenue.' 'Looking ahead, we believe Neo will continue to perform as a double-digit revenue growth company, poised to capture additional market share,' continued Mr. Zook. 'We are enhancing our R&D efforts to develop new therapy selection and next-gen MRD products. We are also preparing for the commercial launch of PanTracer Liquid Biopsy, continuing to grow our sales team, increasing efficiencies, and pursuing partnerships through business development efforts that will enhance our portfolio and strengthen our community channel. We are confident that Neo will deliver long-term value for our customers, patients, and shareholders.' Second-Quarter Results Consolidated revenue for the second quarter of 2025 was $181 million, an increase of 10% over the same period in 2024 primarily due to higher volume partially offset by lower non-clinical revenue. Average revenue per clinical test ('revenue per test') increased by 2% to $465. This increase reflects higher value tests, including NGS, and strategic reimbursement initiatives. Consolidated gross profit for the second quarter of 2025 was $77 million, an increase of 7% compared to the second quarter of 2024. This increase was primarily due to an increase in revenue partially offset by higher compensation and benefit costs and an increase in supplies expense. Consolidated gross profit margin, including amortization of acquired intangible assets and stock-based compensation expense, was 43%. Adjusted Gross Profit Margin (1), excluding amortization of acquired intangible assets and stock-based compensation expense, was 45%. Operating expenses for the second quarter of 2025 were $125 million, an increase of $30 million, or 32%, compared to the second quarter of 2024. The increase in operating expenses primarily reflect $20.0 million of impairment charges from impairment of assets held for sale related to the planned sale of Trapelo and the InVisionFirst®-Lung intangible asset impairments, as well as $4.4 million in higher compensation and benefit costs. These increases were partially offset by a decrease in restructuring activities due to the completion of restructuring activities in the fourth quarter of 2024. Net loss for the quarter increased $26 million, or 142%, to $45 million compared to net loss of $19 million for the second quarter of 2024. Adjusted EBITDA (1) for the second quarter of 2025 remained relatively flat at positive $10.7 million, compared to positive $10.9 million in the second quarter of 2024. Adjusted Net Loss (1) was $3.6 million compared to Adjusted Net Loss (1) of $4 million in the second quarter of 2024. Cash and cash equivalents and marketable securities totaled $164 million at quarter end. Pathline, LLC Acquisition On April 4, 2025, the Company completed the acquisition of a 100% ownership interest in Pathline, LLC ('Pathline'), a CLIA/CAP/NYS-certified laboratory based in New Jersey. The purchase price consisted of (i) initial cash consideration of $8.0 million, subject to working capital and other adjustments, and (ii) contingent consideration of $1.0 million. The Pathline acquisition aligns with the Company's strategic objective of expanding its presence, capabilities, and offerings in the Northeastern United States. 2025 Financial Guidance (2) The Company again revised its full-year 2025 guidance (2), as previously revised on April 29, 2025. ____________________ Expand (1) The Company has provided adjusted financial information that has not been prepared in accordance with GAAP, including Adjusted EBITDA, Adjusted Gross Profit Margin, Adjusted Net (Loss) Income, and Adjusted Diluted EPS. Each of these measures is defined in the section of this report entitled 'Use of Non-GAAP Financial Measures.' See also the tables reconciling such measures to their closest GAAP equivalent. (2) The Company reserves the right to adjust this guidance at any time. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company's securities and are reminded that the foregoing estimates should not be construed as guarantees of future performance. Expand Conference Call The Company has scheduled a webcast and conference call to discuss its second quarter 2025 results on Tuesday, July 29, 2025 at 8:30 a.m. Eastern Time. To access the live call via telephone, interested investors should dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 859170. The live webcast may be accessed by visiting the Investor Relations section of our website at A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company's website. About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. We routinely post information that may be important to investors on our website at Forward Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as 'anticipate,' 'expect,' 'plan,' 'could,' 'would,' 'may,' 'will,' 'believe,' 'estimate,' 'forecast,' 'goal,' 'project,' 'guidance,' 'plan,' 'potential' and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including statements regarding 2025 financial guidance, seasonality impacts, and long-range strategic objectives and initiatives set forth in the Company's long-range plans.. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to assemble and maintain an effective executive team, to continue gaining new customers, offer new types of tests, integrate its acquisitions, manage the effects of seasonality, execute on its long-range strategic priorities, and otherwise implement its business plans, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and filed with the SEC on February 18, 2025, as well as subsequently filed Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and on our website at for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. NeoGenomics, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended June 30, Six Months Ended June 30, COST OF REVENUE 104,072 92,008 198,861 182,779 GROSS PROFIT 77,258 72,494 150,504 137,963 Operating expenses: General and administrative 71,747 63,328 139,954 129,125 Research and development 9,023 7,886 19,204 15,506 Sales and marketing 24,075 21,677 46,758 41,898 Restructuring charges — 1,544 — 3,942 Impairment charges 20,041 — 20,041 — Total operating expenses 124,886 94,435 225,957 190,471 LOSS FROM OPERATIONS (47,628 ) (21,941 ) (75,453 ) (52,508 ) Interest income (2,263 ) (4,592 ) (5,984 ) (9,426 ) Interest expense 933 1,666 2,551 3,351 Other (income) expense, net (482 ) 2 (547 ) 265 Loss before taxes (45,816 ) (19,017 ) (71,473 ) (46,698 ) Income tax benefit (724 ) (375 ) (458 ) (995 ) NET LOSS $ (45,092 ) $ (18,642 ) $ (71,015 ) $ (45,703 ) NET LOSS PER SHARE Basic $ (0.35 ) $ (0.15 ) $ (0.56 ) $ (0.36 ) Diluted $ (0.35 ) $ (0.15 ) $ (0.56 ) $ (0.36 ) WEIGHTED AVERAGE COMMON SHARES OUTSTANDING Basic 127,949 126,405 127,664 126,257 Diluted 127,949 126,405 127,664 126,257 Expand NeoGenomics, Inc. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited) Six Months Ended June 30, 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ (71,015 ) $ (45,703 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 18,506 19,651 Amortization of intangibles 16,486 16,723 Stock-based compensation 22,968 16,615 Non-cash operating lease expense 3,353 4,793 Amortization of convertible debt discount and debt issue costs 1,233 1,452 Impairment charges 20,041 — Other impairment charges — 333 Other adjustments (340 ) 159 Changes in assets and liabilities, net (16,229 ) (26,046 ) Net cash used in operating activities (4,997 ) (12,023 ) CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from maturities of marketable securities 11,060 40,501 Purchases of property and equipment (10,823 ) (18,663 ) Business acquisition, net of cash acquired (5,991 ) — Net cash (used in) provided by investing activities (5,754 ) 21,838 CASH FLOWS FROM FINANCING ACTIVITIES Issuance of common stock, net (234 ) 2,782 Repayment of convertible debt (201,250 ) — Net cash (used in) provided by financing activities (201,484 ) 2,782 Net change in cash and cash equivalents, including cash classified within current assets held for sale (212,235 ) 12,597 Less: net change in cash classified within current assets held for sale (54 ) — Net change in cash and cash equivalents (212,289 ) 12,597 Cash and cash equivalents, beginning of period 367,012 342,488 Cash and cash equivalents, end of period $ 154,723 $ 355,085 Expand Use of Non-GAAP Financial Measures In order to provide greater transparency regarding our operating performance, the financial results and financial guidance in this press release refer to certain non-GAAP financial measures that involve adjustments to GAAP results. Non-GAAP financial measures exclude certain income and/or expense items that management believes are not directly attributable to the Company's core operating results and/or certain items that are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. Management believes that the presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors by facilitating the analysis of the Company's core test-level operating results across reporting periods. These non-GAAP financial measures may also assist investors in evaluating future prospects. Management also uses non-GAAP financial measures for financial and operational decision making, planning and forecasting purposes and to manage the business. These non-GAAP financial measures do not replace the presentation of financial information in accordance with U.S. GAAP financial results, should not be considered measures of liquidity, and are unlikely to be comparable to non-GAAP financial measures provided by other companies. Definitions of Non-GAAP Measures Non-GAAP Adjusted EBITDA 'Adjusted EBITDA' is defined by NeoGenomics as net (loss) income from continuing operations before: (i) interest income, (ii) interest expense, (iii) tax (benefit) or expense, (iv) depreciation and amortization expense, (v) stock-based compensation expense, and, if applicable in a reporting period, (vi) CEO transition costs, (vii) restructuring charges, (viii) impairment charges, (ix) intellectual property ('IP') litigation costs, and (x) other significant or non-operating (income) or expenses, net. Non-GAAP Adjusted Cost of Revenue, Adjusted Gross Profit and Adjusted Gross Profit Margin 'Adjusted cost of revenue' is defined by NeoGenomics as cost of revenue before: (i) amortization of acquired intangible assets, and, if applicable in a reporting period, (ii) stock-based compensation expense. 'Adjusted gross profit' is defined by NeoGenomics as total revenue less adjusted cost of revenue. 'Adjusted gross profit margin' is defined by NeoGenomics as adjusted cost of revenue divided by total revenue. Non-GAAP Adjusted Net (Loss) Income 'Adjusted net (loss) income' is defined by NeoGenomics as net (loss) income from continuing operations plus: (i) amortization of intangible assets, (ii) stock-based compensation expense, and, if applicable in a reporting period, (iii) CEO transition costs, (iv) restructuring charges, (v) impairment charges, (vi) IP litigation costs, and (vii) other significant or non-operating (income) or expenses, net. If GAAP net (loss) income is negative and adjusted net (loss) income is positive, adjusted net (loss) income will also be adjusted to reverse any recognized interest expense (including any amortization of discounts) on the convertible notes using the if-converted method unless the effect of this adjustment on both the adjusted net (loss) income and weighted average diluted common shares outstanding would be anti-dilutive. If GAAP net (loss) income is positive and adjusted net (loss) income is negative, adjusted net (loss) income will also be adjusted to reverse any recognized interest expense (including any amortization of discounts) on the convertible notes using the if-converted method. Non-GAAP Adjusted Diluted EPS 'Adjusted diluted EPS' is defined by NeoGenomics as adjusted net (loss) income divided by adjusted diluted shares outstanding. If GAAP net (loss) income is negative and adjusted net (loss) income is positive, adjusted diluted shares outstanding will also include any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive. If GAAP net (loss) income is positive and adjusted net (loss) income is negative, adjusted diluted shares outstanding will exclude any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period. ____________________ Expand (1) For the three months ended June 30, 2025, CEO transition costs include executive retention costs. For the six months ended June 30, 2025, CEO transition costs include severance costs, executive retention costs, and executive search costs. There were no such costs for the three and six months ended June 30, 2024. (2) For the three and six months ended June 30, 2025, acquisition and integration related expenses include consulting and legal fees, severance costs, and employee retention costs. (3) For the three and six months ended June 30, 2025, impairment charges include losses from InVisionFirst®-Lung intangible asset impairment and inventory write-off, and impairment of disposal groups held for sale. There were no such costs for the three and six months ended June 30, 2024. (4) For the three and six months ended June 30, 2025 and June 30, 2024, IP litigation costs include legal fees. (5) For the three and six months ended June 30, 2024, other significant (income) expenses, net, includes site closure costs, severance costs, and fees related to non-recurring legal matters. There were no such costs for the three and six months ended June 30, 2025. Expand ____________________ Expand (1) Cost of revenue adjustments for the three months ended June 30, 2025, includes $4.8 million of amortization of acquired intangible assets and $0.3 million of stock-based compensation. Cost of revenue adjustments for the six months ended June 30, 2025, includes $9.7 million of amortization of acquired intangible assets and $0.7 million of stock-based compensation. Cost of revenue adjustments for the three months ended June 30, 2024, includes $4.9 million of amortization of acquired intangible assets and $0.3 million of stock-based compensation. Cost of revenue adjustments for the six months ended June 30, 2024, includes $9.8 million of amortization of acquired intangible assets and $0.7 million of stock-based compensation. Expand Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss and GAAP EPS to Non-GAAP Adjusted EPS (in thousands, except per share amounts) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net loss (GAAP) $ (45,092 ) $ (18,642 ) $ (71,015 ) $ (45,703 ) Adjustments to net loss, net of tax: Amortization of intangibles 8,124 8,361 16,486 16,723 CEO transition costs (1) 637 — 2,831 — Acquisition and integration related expenses (2) 3,204 — 4,376 — Stock-based compensation expense 12,215 8,841 22,968 16,615 Restructuring charges — 1,544 — 3,942 Impairment charges (2) 20,041 — 20,041 — IP litigation costs (3) 4,460 1,962 7,443 6,243 Other significant expenses, net (4) — 2,358 — 3,960 Adjusted net income $ 3,589 $ 4,424 $ 3,130 $ 1,780 Net loss per common share (GAAP) Diluted EPS $ (0.35 ) $ (0.15 ) $ (0.56 ) $ (0.36 ) Adjustments to diluted loss income per share: Amortization of intangibles 0.06 0.07 0.13 0.13 CEO transition costs (1) — — 0.02 — Acquisition and integration related expenses (2) 0.03 — 0.03 — Stock-based compensation expense 0.10 0.07 0.18 0.13 Restructuring charges — 0.01 — 0.03 Impairment charges (3) 0.16 — 0.16 — IP litigation costs (4) 0.03 0.02 0.06 0.05 Other significant expenses, net (5) — 0.02 — 0.03 Rounding and impact of diluted shares in adjusted diluted shares (6) — (0.01 ) — — Adjusted diluted EPS (non-GAAP) $ 0.03 $ 0.03 $ 0.02 $ 0.01 Weighted average shares used in computation of adjusted diluted EPS: Diluted common shares (GAAP) 127,949 126,405 127,664 126,257 Dilutive effect of options, restricted stock, and converted shares (7)(8) — — — — Expand ____________________ Expand (1) For the three months ended June 30, 2025, CEO transition costs include executive retention costs. For the six months ended June 30, 2025, CEO transition costs include severance costs, executive retention costs, and executive search costs. There were no such costs for the three and six months ended June 30, 2024. (2) For the three and six months ended June 30, 2025, acquisition and integration related expenses include consulting and legal fees, severance costs, and employee retention costs. (3) For the three and six months ended June 30, 2025, impairment charges include losses from InVisionFirst®-Lung intangible asset impairment and inventory write-off, and impairment of disposal groups held for sale. There were no such costs for the three and six months ended June 30, 2024. (4) For the three and six months ended June 30, 2025 and June 30, 2024, IP litigation costs include legal fees. (5) For the three and six months ended June 30, 2024, other significant (income) expenses, net, includes site closure costs, severance costs, and fees related to non-recurring legal matters. There were no such costs for the three and six months ended June 30, 2025. (6) This adjustment is for rounding and, in those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive or GAAP net (loss) income is positive and adjusted net (loss) income is negative, also compensates for the effects of additional diluted shares included or excluded in adjusted diluted shares outstanding for the treasury stock impact of outstanding stock options and restricted stock and the if-converted impact of convertible notes. (7) In those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, this adjustment includes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive. (8) In those periods in which GAAP net (loss) income is positive and adjusted net (loss) income is negative, this adjustment excludes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period. Expand Reconciliation of Non-GAAP Financial Guidance to Corresponding GAAP Measures (in thousands, except per share amounts) (unaudited) GAAP net loss in 2025 will be impacted by certain charges, including: (i) expense related to the amortization of intangible assets, (ii) stock-based compensation, and (iii) other one-time expenses. These charges have been included in GAAP net loss available to stockholders and GAAP net loss per share; however, they have been removed from adjusted net loss and adjusted diluted net loss per share The following table reconciles the Company's 2025 outlook for net loss and EPS to the corresponding non-GAAP measures of adjusted net loss, adjusted EBITDA, and adjusted diluted EPS: ____________________ Expand (1) This adjustment is for rounding and, in those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, also compensates for the effects of additional diluted shares included in adjusted diluted shares outstanding for the treasury stock impact of outstanding stock options and restricted stock and the if-converted impact of convertible notes. (2) For those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, this adjustment includes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive. Expand Supplemental Information Clinical Tests Performed and Revenue (unaudited) ____________________ Expand (1) Excludes tests and revenue related to Pathline and non-clinical activity. (2) Excludes tests and revenue related to non-clinical activity. Expand
Business Times
a day ago
- Business
- Business Times
First Sponsor reports 59.2% jump in H1 earnings to S$19 million, interim dividend of S$0.011 a share
[SINGAPORE] Property developer First Sponsor reported a 59.2 per cent increase in earnings to S$19 million in H1 2025 from S$11.9 million in H1 2024, in a bourse filing on Monday (Jul 28). The earnings growth was mainly driven by a higher share of profits from associates and joint ventures. However, revenue for H1 2025 fell 11 per cent to S$153.9 million from S$172.9 million in H1 2024. The drop in revenue was mainly the result of a fall in revenue from the sale of development properties, property financing and hotel operations. This was offset by an increase in rental income from investment properties. The company's Chinese projects continued to be dogged by subdued presales amid a prolonged weakness in property market sentiment. Neo Teck Pheng, the developer's chief executive, said: 'The group continues to adopt a long-term perspective on the sales cycle, and has generally refrained from any significant price cut.' The board has approved an interim dividend of S$0.011 a share for FY2025, the same amount as in FY2024. Neo said: 'Backed by a strong balance sheet and substantial unutilised committed credit facilities, the group is in a sound financial position to not only navigate through the geopolitical and economic challenges and uncertainties, but to also capitalise on any favourable business opportunities that may arise.' The company's shares closed unchanged at S$1.05 on Monday.
Straits Times
2 days ago
- Business
- Straits Times
Authorities say access to Changi intertidal areas unaffected by reclamation, in response to petition
Find out what's new on ST website and app. On July 2, The Straits Times reported that about 193ha of land off Changi will be reclaimed – roughly twice the size of Gardens by the Bay. SINGAPORE - Planned reclamation works to expand Changi Aviation Park will not affect access to popular intertidal areas off Changi Beach Park, the Housing Board and Urban Redevelopment Authority (URA) said in a joint statement on July 28. The authorities also said the environmental impact assessment report for the project contained security sensitivities that required confidentiality agreements before the public could view it. They were responding to concerns raised by nature enthusiasts over whether plans for the area will limit public access to the rich shorelines of Changi. At low tides, the area often draws people hoping to glimpse anemones, octopi, and other marine creatures. A petition raised by nature guide Neo Xiaoyun and environmental storyteller Julian Paul Lee called for HDB to scale back its plans for the reclamation in the light of the area's intertidal ecosystem. It also flagged concerns that the Government's consultation of the public over the works had been undermined by its use of non-disclosure agreements. On July 2, The Straits Times reported that about 193ha of land off Changi will be reclaimed – roughly twice the size of Gardens by the Bay. It is one-fifth smaller than originally planned in order to protect one of Singapore's largest seagrass meadows. Top stories Swipe. Select. Stay informed. Singapore Tanjong Katong sinkhole backfilled; road to be repaved after LTA tests Singapore Tanjong Katong Road sinkhole did not happen overnight: Experts Singapore New Mandai North Crematorium, ash-scattering garden to open on Aug 15 Singapore Not feasible for S'pore to avoid net‑zero; all options to cut energy emissions on table: Tan See Leng Singapore With regional interest in nuclear energy rising, S'pore must build capabilities too: Tan See Leng World US and EU clinch deal with broad 15% tariffs on EU goods to avert trade war Asia Displaced villagers at Thai-Cambodian border hope to go home as leaders set to meet for talks The intertidal areas near the project are one of the last accessible places for the public to experience the rich biodiversity of Singapore's shores, Ms Neo and Mr Lee wrote in the open letter created on July 13. To date, more than 1,440 people have signed the petition, which called for the Government to review the use of confidentiality agreements for environmental impact assessments and prioritise public access to non-sensitive information in these reports. Ms Neo and Mr Lee, both 29, wrote that the blanket use of a confidentiality agreement runs counter to the purpose of environmental assessments, which is to incorporate diverse views and protect natural heritage through public input. HDB and URA said it requires the public to view the hard copy of environmental impact assessments if there are considerations requiring confidentiality, including security sensitivities, such as in the case of the Changi North reclamation. They said: 'For such (assessments), rather than not disclose them altogether, we would facilitate the viewing of the reports, both during and after the public disclosure period, but would require viewers to sign a non-disclosure agreement, which covers the specific sensitive information within the report.' The authorities noted that most reports for environmental impact assessments are made online for public feedback for a stipulated period. Giving more details about the reclamation at Changi North, they said Carparks 6 and 7 of Changi Beach Park will not be affected. As part of the planning for the Changi North project, the HDB, in consultation with NParks, had engaged stakeholders who have local conservation experience and technical knowledge of the area's biodiversity and habitats. These included nature groups, youth representatives and academics. Ms Neo told ST that she welcomed the authorities' time and effort to engage with the petition, although there was still room for improvement. 'The use of confidentiality agreements are still worded quite broadly, so this still creates a chilling effect that dissuades meaningful civic engagement,' said the master's student studying geography and environment at the University of Hawaii. She suggested that the agencies and contractors for future assessments could consider consulting nature guides familiar with the affected areas, as their years of observational data and experience can complement surveys. The public feedback period for the proposed land reclamation works at Changi North has closed, but members of the public can still e-mail HDB to view the report. The reclamation project off Changi North is one of several to create more land at the eastern end of Singapore, including the reclamation of about 900ha off Changi Bay.
Straits Times
2 days ago
- Politics
- Straits Times
Younger generation must inherit and strengthen Singapore's multiculturalism: David Neo
Acting Minister for Culture, Community and Youth David Neo speaking at Kaleidoscope: Harmony in Motion on July 27. SINGAPORE – Singapore's multiculturalism must continue to be core to the country's shared values as it looks to SG100, and this is something the younger generation must inherit, strengthen and pass on, said Acting Minister for Culture, Community and Youth David Neo. This multiculturalism is a unique strength and especially crucial in an increasingly divided world, said Mr Neo as he addressed around 500 youth participants at the inaugural Kaleidoscope: Harmony in Motion showcase. 'Our multiracial, harmonious and cohesive society is a priceless asset that generations of Singaporeans have collectively nurtured,' he said. 'It underpins our safety and security and allows us to bring our families up in peace and pursue our dreams to go further.' Held on the evening of July 27 at the Singapore Chinese Cultural Centre, the youth-led cultural showcase and community fair was the collective effort of over 100 young people from 10 religions and 25 community and faith-based organisations. Mr Neo said he was heartened to see Singapore's youth step forward to lead efforts on the multiculturalism front, stressing that it was more important than ever in a fractured, increasingly divided world. He said Singapore is not immune to vulnerabilities such as 'new driving forces that seek to pull us apart' – citing the spread of misinformation and the subsequent creation of echo chambers as an example. Top stories Swipe. Select. Stay informed. Singapore Sewage shaft failure linked to sinkhole; PUB calling safety time-out on similar works islandwide Singapore Tanjong Katong Road sinkhole did not happen overnight: Experts Singapore Workers used nylon rope to rescue driver of car that fell into Tanjong Katong Road sinkhole Asia Singapore-only car washes will get business licences revoked, says Johor govt World Food airdropped into Gaza as Israel opens aid routes Sport Arsenal beat Newcastle in five-goal thriller to bring Singapore Festival of Football to a close Singapore Benchmark barrier: Six of her homeschooled kids had to retake the PSLE Asia S'porean trainee doctor in Melbourne arrested for allegedly filming colleagues in toilets since 2021 'Our youth are our future... We need to create space for them to have a voice and to have a hand in shaping our future Singapore society,' added Mr Neo, who is also Senior Minister of State for Education. It was a sentiment shared by 18-year-old Thaddeus Tan, one of the youngsters leading Kaleidescope and who has been a grassroots member in MacPherson since the age of 13. He said his experience on the ground gave him a different perspective on the increasingly diverse concerns among young people. 'It made me realise that young people require a national-level platform to both showcase their skills and talents, and their concerns about issues like social, racial and religious harmony that extend beyond a (one-off) Racial Harmony Day,' said Thaddeus, a student in Nanyang Junior College. 'By bringing this to a national level, we are actually telling the youth: We appreciate you and it's important that you have a seat at the table.' Civil servant Didi Amzar, 27, one of the youth leaders in the Racial and Religious Harmony Circle and a leader of the Kaleidoscope project, said: 'There have been youth-led events in the past but definitely not something of this scale and in this format.' Mr Didi Amzar (right) and Mr Thaddeus Tan at the inaugural Kaleidoscope: Harmony in Motion showcase. PHOTO: LIANHE ZAOBAO The Racial and Religious Harmony Circle currently has more than 1,700 members, including representatives from religious organisations, civic groups and grassroots organisations from across Singapore. Mr Didi, who conceptualised and shaped the storyline for the Kaleidoscope: Harmony in Motion showcase, said he wanted to feature 'the real diversity of Singapore' beyond the standard Chinese-Malay-Indian-Others communities to also feature the often overlooked 'in-betweens'. Hence, the production, a three-act performance about three young protagonists' aspirations for a harmonious society, featured actors of mixed-race heritage for a more inclusive representation of Singaporeans. 'The youth leaders have to find a solution to unite their tribes and society, and I think that's a really good reminder – that if we really want youth leaders to be the future generation leading us forward, we have to give them the chance to do so,' he said. The Kaleidescope event also featured a fair with interactive booths, cultural demonstrations by musicians, and sharing sessions on the various religions in Singapore by partners such as the Inter-Religious Organisation; Climate Interfaith; Dialogue Centre; and Roses of Peace. The event concluded Singapore's Racial and Religious Harmony Month celebrations. Racial Harmony Day is celebrated on July 21, with July designated as Racial and Religious Harmony Month since 2023. In 2025 , Harmony Circle and community partners organised more than 60 activities, bringing together more than 100,000 people through sports, arts, carnivals, dialogues and tours.
Cision Canada
22-07-2025
- Business
- Cision Canada
Media Advisory - Neo Performance Materials Inc. Second Quarter 2025 Earnings Release & Webcast
TORONTO, July 22, 2025 /CNW/ - Neo Performance Materials Inc. (" Neo" or the " Company") (TSX: NEO) (OTCQX: NOPMF) will report its second-quarter results for the period ended June 30, 2025, before the Toronto market opens on Tuesday, August 12, 2025. Teleconference Details Date: Tuesday, August 12, 2025 Time: 10:00 AM ET | 7:00 AM PT Webcast: LINK Conference call: 1-416-945-7677 (local) or 1-888-699-1199 (toll-free long distance) or by visiting Dial-in Link. A replay of the webcast will be available by clicking on the webcast LINK above and will be archived on the Company's website for a limited period. A teleconference recording may be accessed by calling 1-289-819-1450 (local) or 1-888-660-6345 (toll-free long distance) and entering passcode 04579# until September 12, 2025. About Neo Performance Materials Neo manufactures the building blocks of many modern technologies that enhance efficiency and sustainability. Neo's advanced industrial materials – magnetic powders, rare earth magnets, magnetic assemblies, specialty chemicals, metals, and alloys – are critical to the performance of many everyday products and emerging technologies. Neo's products fast-forward technologies for the net-zero transition. The business of Neo is organized along three segments: Magnequench, Chemicals & Oxides and Rare Metals. Neo is headquartered in Toronto, Ontario, Canada; with corporate offices in Greenwood Village, Colorado, United States; Singapore; and Beijing, China. Neo has a global platform that includes manufacturing facilities located in China, Germany, Canada, Estonia, Thailand and the United Kingdom, as well as a dedicated research and development center in Singapore. For more information, please visit SOURCE Neo Performance Materials, Inc.
